ALPA
Alpa Laboratories financials
- Market cap
- ₹130 Cr
- Sector
- Healthcare
What Alpa Laboratories Limited does
Alpa Laboratories is a pharmaceutical company headquartered in Indore, Madhya Pradesh, established in 1988, that manufactures branded generic formulations through integrated in-house manufacturing facilities. Its products are sold across both domestic and international markets, with manufacturing built to comply with international regulatory quality norms. The company is developing an additional manufacturing site at Pithampur, Madhya Pradesh, to expand its production capacity.
- Markets served
- Domestic and international pharmaceutical markets
- Manufacturing footprint
- Integrated in-house manufacturing facilities in India; new site being developed at Pithampur, Madhya Pradesh for capacity expansion
Quarterly results
Q1 FY27: revenue up 25.2%, net profit down 91.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 26 | 40 | 19 | 26 +5% | 29 +11% | 31 −21% | 24 +25% |
| EBITDA | 3 | 1 | 0 | 0 | -2 −168% | 2 +104% | 4 +1700% | -4 −1021% |
| Net profit | 8 | 9 | -2 | 12 | 0 −99% | 2 −82% | 1 +165% | 1 −92% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −34.8% 1Y
1Y: ₹94.6 on 10 Sept 2025 → ₹61.69. High ₹95.43 (11 Sept 2025), low ₹46.46 (30 Mar 2026).
Financials, as filed
Revenue grew 4.8% a year over 3 years, FY23 to FY26. Operating margin narrowed to 3.1%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹92 Cr | ₹109 Cr | ₹112 Cr | ₹106 Cr |
| Operating profit | ₹7 Cr | ₹8 Cr | ₹5 Cr | ₹3 Cr |
| Operating margin | 7.8% | 7.5% | 4.3% | 3.1% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Net profit | ₹13 Cr | ₹17 Cr | ₹20 Cr | ₹15 Cr |
| Net margin | 14.1% | 15.5% | 17.4% | 14.0% |
| Cash from operations | ₹9 Cr | ₹4 Cr | ₹18 Cr | ₹10 Cr |
| Free cash flow | ₹8 Cr | ₹-3 Cr | ₹7 Cr | ₹6 Cr |
| ROCE | 12.0% | 15.0% | 16.0% | 9.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr |
| Reserves | ₹87 Cr | ₹101 Cr | ₹114 Cr | ₹144 Cr | ₹162 Cr | ₹165 Cr |
| Borrowings | ₹0 Cr | ₹6 Cr | ₹2 Cr | ₹2 Cr | ₹0 Cr | ₹3 Cr |
| Other liabilities | ₹33 Cr | ₹28 Cr | ₹30 Cr | ₹32 Cr | ₹54 Cr | ₹53 Cr |
| Total liabilities | ₹140 Cr | ₹155 Cr | ₹167 Cr | ₹199 Cr | ₹238 Cr | ₹242 Cr |
| Fixed assets | ₹7 Cr | ₹9 Cr | ₹7 Cr | ₹11 Cr | ₹21 Cr | ₹20 Cr |
| Capital work in progress | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹51 Cr | ₹75 Cr | ₹78 Cr | ₹116 Cr | ₹145 Cr | ₹142 Cr |
| Other assets | ₹81 Cr | ₹71 Cr | ₹82 Cr | ₹72 Cr | ₹71 Cr | ₹80 Cr |
| Total assets | ₹140 Cr | ₹155 Cr | ₹167 Cr | ₹199 Cr | ₹238 Cr | ₹242 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −0.10 pp. The shareholder count shrank 6% to 17,643.
- Promoters
- 57.2%
- FIIs
- 0.3%
- DIIs
- 0.1%
- Public
- 42.4%
Since Jun 2025
- Promoters −0.10 pp
- DIIs +0.07 pp
- Public +0.04 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 57.3%, FIIs 0.1%, Public 42.6%.Dec '23: Promoters 57.3%, FIIs 0.9%, Public 41.7%.Mar '24: Promoters 57.3%, FIIs 0.5%, Public 42.2%.Jun '24: Promoters 57.3%, FIIs 0.4%, Public 42.4%.Sep '24: Promoters 57.3%, FIIs 0.7%, Public 42.0%.Dec '24: Promoters 57.3%, FIIs 0.3%, Public 42.3%.Mar '25: Promoters 57.3%, FIIs 0.4%, Public 42.3%.Jun '25: Promoters 57.3%, FIIs 0.4%, Public 42.3%.Sep '25: Promoters 57.3%, FIIs 0.3%, Public 42.4%.Dec '25: Promoters 57.3%, FIIs 0.4%, Public 42.4%.Mar '26: Promoters 57.2%, FIIs 0.4%, Public 42.4%.Jun '26: Promoters 57.2%, FIIs 0.3%, DIIs 0.1%, Public 42.4%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Alpa Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Paresh Chawla | 34.26% | unchanged |
| Shitul Shah | 10.15% | unchanged |
| Bakulesh Shah | 4.88% | unchanged |
| Rima Shah | 3.68% | unchanged |
| Rupal Shah | 2.66% | unchanged |
| Soni Chawla | 1.55% | unchanged |
| Pooja Chawla | 0.00% | unchanged |
| Mitin Shah | 0.00% | unchanged |
| Sarawati Shah | 0.00% | unchanged |
| Mahendra Singh Chawla | 0.00% | unchanged |
| Pravin Shah | 0.00% | unchanged |
| Asha Chawla | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Alpa Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.